Neurologists managing progressive conditions such as ALS, multiple system atrophy, Parkinson’s disease, and traumatic brain injury increasingly encounter patients asking about stem cells and whether to bank their own tissue. This guide gives clinicians an accurate read on the adipose-derived trial pipeline, the procedural timing questions that come up in neurology, and how to introduce banking to a patient without creating false expectations.
TLDR: Several early-phase trials are studying autologous adipose-derived or mesenchymal stem cells in neurologic conditions, including intrathecal programs at Mayo Clinic for ALS and multiple system atrophy, but these studies are early and the two flagship programs are no longer enrolling. No adipose-derived product holds FDA approval for any neurologic condition. Banking preserves a patient’s own adipose tissue under 21 CFR Part 1271; it does not slow or alter neurologic disease, it does not enroll a patient in any trial, and it does not guarantee eligibility, access, or clinical benefit. Procedural timing for an elective harvest is a clinical judgment that depends on the patient’s disease stage and overall status.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including neurological conditions. No adipose-derived stem cell product currently has FDA approval for any neurologic condition. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Neurologic diagnoses carry urgency and emotion, which makes accurate framing essential. The sections below summarize what is genuinely active in the pipeline, why procedural timing matters for an elective harvest, and how to document a banking discussion responsibly.
The Neurology ADSC Trial Pipeline: What Is Active in 2026
Research interest in mesenchymal and adipose-derived stem cells for neurologic disease centers on their studied influence on inflammatory and cellular signaling, not on any demonstrated ability to restore lost neurologic function. The pipeline is early, and a clinician should read it as a set of investigational questions rather than emerging therapies.
Two programs at Mayo Clinic illustrate the state of the field. An ALS study, NCT03268603, is evaluating autologous adipose-derived mesenchymal stromal cells administered intrathecally in a Phase 2 design, and it is currently active but no longer recruiting. A multiple system atrophy study, NCT05167721, is a randomized, placebo-controlled Phase 2 trial of intrathecally administered autologous mesenchymal stem cells, also active and no longer recruiting. A separate Phase 2 study of autologous adipose-derived cells in chronic traumatic brain injury, sponsored by Hope Biosciences, is recruiting. For the underlying science, the overview of adipose-derived cells in neurology provides additional depth, and the broader set of active clinical trials shows where these sit relative to other programs.
Two cautions belong with each reference. First, registration confirms a study exists; it does not mean a therapy is approved, effective, or available. Second, the fact that the two flagship neurology programs are closed to enrollment underscores a point patients often miss: the existence of a trial does not mean a patient can join it, and banking does not change that.
ALS: Why the Harvest Window Is Time-Sensitive
In ALS, procedural timing for an elective harvest is a legitimate clinical consideration, and it is best framed in operational terms rather than therapeutic ones. As the disease progresses, declining respiratory function, positioning tolerance, and nutritional status raise the risk profile of any elective procedure. A patient who is earlier in the disease course is generally a more straightforward candidate for an elective collection than one with significant respiratory compromise.
This is a procedural and safety point, not a claim of benefit. Banking does not slow ALS or alter its course, and that boundary must be explicit in any patient discussion. The reason timing matters is that the harvest itself is an elective procedure whose safety depends on the patient’s current physiologic status, which a treating physician assesses individually.
| Disease stage | Considerations for an elective harvest |
| Recently diagnosed, minimal functional loss | Respiratory and nutritional status are typically more stable, which generally simplifies elective procedural assessment |
| Moderate progression | Pulmonary function, positioning tolerance, and anesthetic risk become central to whether an elective procedure is advisable |
| Advanced disease | Elevated respiratory and anesthetic risk often make an elective harvest inadvisable; the treating physician weighs this individually |
The table reflects general procedural considerations, not a recommendation. Every decision belongs to the treating neurologist and the proceduralist, who assess the individual patient.
Multiple System Atrophy: The MSA Trial and Banking Timing
Multiple system atrophy progresses through autonomic and motor dysfunction, and like ALS it raises procedural-timing questions for any elective collection. Autonomic instability, including orthostatic and cardiovascular considerations, is part of the risk assessment a physician makes before an elective procedure. As with ALS, an earlier point in the disease course is often a more straightforward setting for an elective harvest, though this is an individual clinical judgment.
The Mayo MSA trial, NCT05167721, is a randomized, placebo-controlled Phase 2 study using autologous cells delivered intrathecally, and it is active but no longer recruiting. That status is worth communicating directly to patients, because it illustrates that even a well-known program may be closed to new participants. Banking preserves a patient’s own tissue; it does not provide access to this or any other study, and it does not influence the course of MSA.
Introducing Banking to a Newly Diagnosed Neurological Patient
Introducing banking to a recently diagnosed patient calls for care, because the moment is emotionally charged and the temptation to hear banking as a treatment is strong. The honest framing is that banking is a preservation decision, made under uncertainty, that stores a patient’s own tissue for potential future use. It is not a therapy, it does not slow the disease, and it does not guarantee that any future pathway will exist or apply.
A clinician can present banking as one optional consideration among many, with realistic expectations attached. It helps to explain what the service is and is not, to note that the current adipose-derived neurology trials are early and in key cases closed to enrollment, and to direct the patient to verifiable information. The explanation of why physicians add banking describes the service model, and the provider-facing summary of the harvest procedure outlines how collection is handled. Setting expectations carefully protects both the patient and the practice.
Documenting the Banking Discussion in the Chart
Documentation matters when a banking conversation occurs in a neurology practice. The chart should reflect that banking was discussed as an elective preservation option, that the patient was counseled it is not a treatment and offers no guarantee of trial access or clinical benefit, and that any decision was the patient’s own. Recording the educational nature of the discussion is consistent with maintaining clear boundaries around scope of practice.
It is also appropriate to document that the patient was advised to make medical decisions in consultation with the appropriate specialists, and that banking does not replace disease-directed care. A clinician should ensure that separate, specific informed consent for tissue banking is obtained and retained, distinct from consent for any clinical service the practice provides.
Expanded Access for Patients Who Cannot Enroll
For patients who cannot join a trial, Expanded Access is sometimes raised, and it deserves an accurate description. Expanded Access is a physician-initiated pathway with full FDA and institutional review board oversight; a patient cannot apply directly, and the treating physician submits the request. Manufacturer willingness, product stage, and eligibility all govern whether access is possible, and there is no general Expanded Access pathway for banked adipose tissue.
The key point for patients is that banking does not connect a person to Expanded Access or to any trial. The overview of expanded access explains how these pathways function and what they require. A neurologist can help a patient understand realistic options without implying that stored tissue creates eligibility.
Physician Action Checklist
Before introducing banking into a neurology practice, a clinician can work through a short operational list:
- Confirm that patient-facing language never implies banking slows, alters, or treats a neurologic condition, and that it states no adipose-derived product is FDA-approved for any neurologic indication.
- Assess elective-harvest timing individually, accounting for respiratory, autonomic, nutritional, and anesthetic risk relevant to the patient’s disease stage.
- Communicate the current enrollment status of relevant trials accurately, including that the flagship Mayo ALS and MSA programs are no longer recruiting.
- Document the banking discussion as educational and elective, with explicit counseling that it offers no guarantee of trial access or clinical benefit.
- Ensure separate, specific informed consent for tissue banking, and confirm the banking partner operates under 21 CFR Part 1271 for screening, processing, and storage.
Frequently Asked Questions
Is there an FDA-approved adipose stem cell therapy for any neurologic condition?
No. Several early-phase trials are studying autologous adipose-derived or mesenchymal cells in conditions such as ALS and multiple system atrophy, but no adipose-derived product holds FDA approval for any neurologic disease.
Can a patient enroll in the Mayo ALS or MSA trials by banking tissue?
No. Both programs, NCT03268603 and NCT05167721, are active but no longer recruiting, and trial enrollment is controlled by investigators under specific criteria. Banking preserves a patient’s own tissue and does not create eligibility for any study.
Does banking slow ALS, MSA, or other neurologic disease?
No. Banking is a preservation service that stores a patient’s own adipose tissue for potential future use. It does not slow or alter neurologic disease and is not a treatment.
Why does the timing of a harvest matter in ALS?
Because the harvest is an elective procedure whose safety depends on the patient’s current status. Declining respiratory and nutritional function in advancing ALS raises procedural risk, so earlier collection is often more straightforward. This is a procedural consideration, not a claim of benefit, and the decision belongs to the treating physician.
How is adipose tissue banking regulated?
Banked adipose tissue is handled under 21 CFR Part 1271, the federal framework governing screening, processing, and storage of human cells and tissues.
Key Takeaways
For neurologists, an accurate read of the adipose pipeline protects patients from false hope. Several early-phase trials are studying autologous adipose-derived or mesenchymal stem cells in neurologic conditions, including intrathecal Phase 2 programs at Mayo Clinic for ALS, NCT03268603, and multiple system atrophy, NCT05167721, but these studies are early and both flagship programs are no longer enrolling. No adipose-derived product is FDA-approved for any neurologic condition. Procedural timing for an elective harvest is a clinical judgment that depends on disease stage and overall status, framed as a safety consideration rather than a therapeutic one. Banking does not connect a patient to any trial or to Expanded Access, and documentation should reflect that any banking discussion was educational and elective. Above all, banking adipose tissue is a preservation service for potential future use; it does not slow or alter neurologic disease, and it does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Neurologists weighing whether to introduce a preservation service can review the service model and contact the team to discuss integration and documentation requirements.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
Related guide: the physician resource center.
